|
Contents |
|
|
|
|
|
|
Astrocytic
Tumors |
|
|
|
Zagzag
D, Friedlander DR, Miller DC, Dosik J, Cangiarella J, Kostianovsky M,
Cohen H, Grumet M, Greco MA
Tenascin
expression in astrocytomas correlates with angiogenesis
Cancer Res. 1995 Feb 15; 55(4): 907-14.
|
|
|
Basic
and Translational Inv. |
|
|
|
Joussen
AM, Kruse FE, Volcker HE, Kirchhof B
Topical
application of methotrexate for inhibition of corneal angiogenesis
Graefes
Arch Clin Exp Ophthalmol 1999 Nov;237(11):920-7
|
|
Murata
T, He S, Hangai M, Ishibashi T, Xi XP, Kim S, Hsueh WA, Ryan SJ, Law RE,
Hinton DR
Peroxisome
proliferator-activated receptor-gamma ligands inhibit choroidal
neovascularization
Invest Ophthalmol Vis Sci 2000 Jul;41(8):2309-17
(PDF Full Text)
|
|
Gagliardi AR, Hennig B, Collins DC
Antiestrogens inhibit endothelial cell growth
stimulated by angiogenic growth factors
Anticancer Res 1996 May-Jun;16(3A):1101-6
|
|
Gilbertson-Beadling
S, Powers EA, Stamp-Cole M, Scott PS, Wallace TL, Copeland J, Petzold G,
Mitchell M, Ledbetter S, Poorman R
The
tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro
by a non-metalloproteinase-dependent mechanism
Cancer
Chemother Pharmacol 1995;36(5):418-24
|
|
|
Brain Tumors |
|
|
| |
Myriam
W Ben Arush, Sergey Postovsky, Ronit Elhasid, A Ben-Barak, C Levine,
Joseph F Guilburd
Antiangiogenic therapy in pediatric malignancies:
experience of the Northern Israel Pediatric Cancer Center
ASCO Proceedings, 2002
Annual Meeting, Abstract No. 2926
|
|
|
MacDonald TJ, Stewart CF, Kocak M, Goldman S,
Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun
LE
Phase I clinical trial of cilengitide in children with refractory brain
tumors: Pediatric Brain Tumor Consortium Study PBTC-012
J
Clin Oncol. 2008 Feb 20;26(6):919-24
 Abstract |
DBLinks | BL 7:6
|
|
|
Cancer
Research |
|
|
|
Arbiser
JL, Klauber N, Rohan R, van Leeuwen R, Huang MT, Fisher C, Flynn E, Byers HR
Curcumin is an
in vivo inhibitor of angiogenesis
Mol
Med 1998 Jun;4(6):376-83
|
|
Boehm
T, Folkman J, Browder T, O'Reilly MS
Antiangiogenic
therapy of experimental cancer does not induce acquired drug resistance
Nature 1997 Nov 27;390(6658):404-7
|
|
Jiang
C, Agarwal R, Lu J
Anti-angiogenic
potential of a cancer chemopreventive flavonoid antioxidant, silymarin:
inhibition of key attributes of vascular endothelial cells and angiogenic
cytokine secretion by cancer epithelial cells
Biochem Biophys Res Commun 2000 Sep 16;276(1):371-8
|
|
Cai
J, Jiang WG, Mansel RE
Inhibition
of angiogenic factor- and tumour-induced angiogenesis by gamma linolenic acid
Prostaglandins
Leukot Essent Fatty Acids 1999 Jan;60(1):21-9
|
|
Yihai
Cao and Renhai Cao
Angiogenesis inhibited by drinking tea
Nature 1999 Apr 1;398(6726):381
|
|
Gorski
DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP,
Soff GA, Kufe DW, Weichselbaum RR
Potentiation of the antitumor effect of ionizing
radiation by brief concomitant exposures to angiostatin
Cancer Res 1998 Dec 15;58(24):5686-9
|
|
Guba
M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ,
Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK
Rapamycin inhibits primary and metastatic tumor growth
by antiangiogenesis: involvement of vascular endothelial growth factor
Nat Med 2002 Feb;8(2):128-35
|
|
Kanoh
T, Matsunaga K, Saito K, Fujii T
Suppression of in vivo tumor-induced angiogenesis by
the protein-bound polysaccharide PSK
In Vivo 1994 Mar-Apr;8(2):247-50
|
|
Li D, Williams JI, Pietras RJ
Squalamine
and cisplatin block angiogenesis and growth of human ovarian cancer cells with
or without HER-2 gene overexpression
Oncogene 2002 Apr 25;21(18):2805-14
|
|
Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A,
Maestroni GJ
Anti-angiogenic
activity of melatonin in advanced cancer patients
Neuroendocrinol
Lett 2001;22(1):45-7
|
|
Majewski
S, Skopinska M, Marczak M, Szmurlo A, Bollag W, Jablonska S
Vitamin D3 is a potent inhibitor of tumor
cell-induced angiogenesis
J Investig
Dermatol Symp Proc 1996 Apr;1(1):97-101
|
|
Redman
BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD
Phase II
trial of tetrathiomolybdate in patients with advanced kidney cancer
Clin Cancer Res. 2003 May;9(5):1666-72
|
|
Verheul
HM, Panigrahy D, Yuan J, D'Amato RJ
Combination
oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth
in rabbits
Br J
Cancer 1999 Jan;79(1):114-8
|
|
Xin X, Yang S, Kowalski J, Gerritsen ME
Peroxisome proliferator-activated receptor gamma ligands
are potent inhibitors of angiogenesis in vitro and in vivo
J
Biol Chem 1999 Mar 26;274(13):9116-21 (FPD
Full Text)
|
|
Yokoyama
Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S
Synergy
between angiostatin and endostatin: inhibition of ovarian cancer growth
Cancer Res 2000 Apr 15;60(8):2190-6 (PDF Full Text)
|
|
Yoshiji
H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T,
Tsujinoue H, Fukui H
The
angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth
and angiogenesis: possible role of the vascular endothelial growth factor
Clin Cancer Res 2001 Apr;7(4):1073-8 (PDF Full
Text)
|
|
Zhou
JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK
Soybean
phytochemicals inhibit the growth of transplantable human prostate carcinoma and
tumor angiogenesis in mice
J Nutr 1999
Sep;129(9):1628-35
|
|
|
Glioblastoma |
|
|
| |
S. Brem, S. A. Grossman, K. A.
Carson, P. New, S. Phuphanich, J. B. Alavi, T. Mikkelsen, R. Priet
Phase II trial of copper depletion as angiosuppressive
treatment in newly diagnosed Glioblastoma Multiforme: Final report
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1530
|
|
Michael
A. Badruddoja, Hendrikus G. J. Krouwer, Scott D. Rand, Kelly J. Rebro,
Arvind P. Pathak, Kathleen M. Schmainda
Antiangiogenic effects of dexamethasone in 9L
gliosarcoma assessed by MRI cerebral blood volume maps
Neuro-Oncology,
Volume 5, Number 4, Pages 235 -- 243 (October
2003)
|
|
Christiana
Charalambous, Johanna Milan, Ligaya Pen, Florence Hofman, and Thomas Chen
The role of IL-8 in the regulation of
normal and tumor-derived human brain endothelial cells
Society for Neuro-Oncology Eighth Annual
Meeting. Keystone, Colorado. November 13–16, 2003. Abstract No. AN-06.
Neuro-Oncology, Volume 5, Issue 4, October 2003
|
| |
C. Conrad, H. Friedman, D. Reardon,
J. Provenzale, E. Jackson, H. Serajuddin, D. Laurent, B. Chen, W. K. A. Yung
A phase I/II trial of single-agent PTK 787/ZK 222584
(PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent
glioblastoma multiforme (GBM)
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1512
|
|
|
Gerstner ER, Duda DG, Tomaso ED, Sorensen G,
Jain RK, Batchelor TT
Antiangiogenic agents for the treatment of glioblastoma
Expert Opin Investig Drugs. 2007 Dec;16(12):1895-1908
Abstract |
DBLinks
|
| |
Jo
Glass, Gruber Michael , Anit Nirenberg
Phase I/II Study of Carboplatin and Thalidomide in
Recurrent Glioblastoma Multiforme
ASCO
Proceedings, 1999 Annual Meeting, Abstract
No.
551
|
|
|
Reardon DA, Wen PY, Desjardins A, Batchelor TT,
Vredenburgh JJ.
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy
Expert Opin Biol Ther. 2008 Apr;8(4):541-53
Abstract |
DBLinks | BL 7:7
|
| |
D. Reardon, H. Friedman, W. K. A. Yung, M. Brada, C. Conrad, J. Provenzale,
E. Jackson, H. Serajuddin, B. Chen, D. Laurent
A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis
inhibitor, in combination with either temozolomide or lomustine for patients
with recurrent glioblastoma multiforme (GBM)
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1513
|
| |
D.
Reardon, H. S. Friedman, W. K. A. Yung, M. Brada, C. Conrad, J. Provenzale,
E. F. Jackson, H. Serajuddin, D. Laurent, D. Reitsma
A
phase I trial of PTK787/ZK 222584 (PTK/ZK), an oral VEGF tyrosine kinase
inhibitor, in combination with either temozolomide or lomustine for patients
with recurrent glioblastoma multiforme (GBM)
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 412
|
|
|
Saidi A, Javerzat S, Bellahcène A, De Vos J,
Bello L, Castronovo V, Deprez M, Loiseau H, Bikfalvi A, Hagedorn M
Experimental anti-angiogenesis causes upregulation of genes associated with
poor survival in glioblastoma
Int
J Cancer. 2007 Dec 18; [Epub ahead of print]
Abstract |
DBLinks | BL 7:2
|
|
Snowden
AW, Zhang L, Urnov F, Dent C, Jouvenot Y, Zhong X, Rebar EJ, Jamieson
AC, Zhang HS, Tan S, Case CC, Pabo CO, Wolffe AP, Gregory PD
Repression
of vascular endothelial growth factor A in glioblastoma cells using
engineered zinc finger transcription factors
Cancer Res. 2003 Dec
15;63(24):8968-76.
|
|
|
Wong
ET, Brem S.
Taming glioblastoma: targeting angiogenesis.
J
Clin Oncol. 2007 Oct 20;25(30):4705-6.
Full Text
| 
Reprint
|
| |
W.
K. A. Yung, H. Friedman, C. Conrad, D. Reardon, J. Provenzale, E. Jackson,
N. Leeds, H. Serajuddin, D. Laurent, D. Reitsma
A
phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine
kinase inhibitor, in patients with recurrent glioblastoma multiforme
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 395
|
| |
W.K.
A Yung, Henry Friedman, E Jackson, J Provenzale, N Leeds, C Conrad, A
Walker, A Henry, J Huang, D Laurent, M Dugan
A
phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in
recurrent glioblastoma
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. 315
|
|
Mateo Ziu, Nils O. Schmidt, Yanping Sun,
Mitchell Albert, Peter M. Black, Rona S. Carroll
Local delivery of anti-angiogenic compounds to human
orthotopic glioblastoma xenografts improves treatment efficacy and survival
Proceedings of the AACR, Volume 44, 2nd ed., July 2003, Abstract No. 6464
|
|
|
Gliomas |
|
|
|
H. A.
Fine, L. Kim, C. Royce, D. Draper, I.
Haggarty, H. Ellinzano, P. Albert, P. Kinney, L. Musib, D. Thornton
Results from phase II trial of Enzastaurin (LY317615) in patients with
recurrent high grade gliomas
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1504.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1504
|
|
H. A. Fine, L. Kim, C. Royce, S. Mitchell, J. P. Duic, P.
Albert, L. Musib, D. Thornton
A phase II trial of LY317615 in patients with recurrent
high grade gliomas
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1511
|
|
HA
Fine, JS Loeffler, A Kyritsis, P Wen, PM Black, VA Levin, S Graham, WKA Yung
A phase II trial of the
anti-angiogenic agent,
thalidomide, in patients with recurrent high-grade gliomas
ASCO
Proceedings, 1997 Annual Meeting, Abstract No. 1372
|
|
Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY,
Steck PA, Kyritsis AP, Yung WK
Antiangiogenesis treatment for gliomas: transfer of
antisense-vascular endothelial growth factor inhibits tumor growth in vivo
Cancer Res
1999 Feb 15;59(4):895-900 (PDF Full Text)
|
|
|
Reardon DA, Desjardins A, Rich JN, Vredenburgh
JJ
The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma
Curr Treat Options Oncol. 2008 Feb 7; [Epub ahead of print]
Abstract |
DBLinks | BL 7:4
|
|
|
Medulloblastoma |
|
|
|
|
Grizzi F, Weber C, Di Ieva A.
Anti-angiogenic strategies in medulloblastoma: reality or mystery?
Pediatr Res. 2008 Jan 24; [Epub ahead of print]
Abstract |
DBLinks | BL 7:6
|
|
|
Metastatic
Tumors |
|
|
| |
Brewer
GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG,
Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD
Treatment
of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic
agent: Phase I study
Clin
Cancer Res 2000 Jan;6(1):1-10 (PDF Full Text)
|
|
|
Oligodendroglial
Tumors
|
|
|
|
B. S. Abdulkarim, A. Hasbini, J.
Cougnard, L. Djafari, C. Lacroix, F. Parker, C. Haie, C. Cioloca, E. Deutsch, E.
Raymond
Baseline pathological and radiological assessment
of tumor angiogenesis predicts survival in patients with oligodendrogliomas
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1545
|
bottom
|
